The meeting that decides what happens next
Twelve peptides came off the FDA's restricted Category 2 list back in April: BPC-157, CJC-1295, GHK-Cu, Ipamorelin, TB-500, AOD-9604, Selank, Semax, and a few others. That was a real step forward, but it never meant compounding pharmacies were cleared to make and dispense them. That's a separate decision, and it lands July 23-24, when the FDA's Pharmacy Compounding Advisory Committee meets to weigh in.
This week added a wrinkle worth knowing about before the meeting happens. NPR reported that FDA's own scientific staff, not outside critics, are recommending against changing the compounding status of the peptides currently under review. NPR also flagged that several committee members have industry ties to peptide clinics or compounding pharmacies that would benefit financially from a favorable vote. Neither fact decides the outcome on its own, but together they're the kind of thing worth watching closely rather than assuming will just sort itself out.
We wrote up the full backstory, including how Category 2 removal differs from a 503A compounding clearance, and what the internal pushback actually means for the meeting's odds.
Full story: What the July PCAC Meeting Means for Your Peptides
If you want your own comment on the record, FDA advisory committee dockets open for public comment through regulations.gov. Search regulations.gov for "Pharmacy Compounding Advisory Committee" closer to the meeting date to find the specific open docket — the comment window for this particular meeting wasn't live as of this issue, but it's worth bookmarking and checking back before July 23.
Search FDA dockets on regulations.gov
Price snapshot: DSIP vs. Epithalon
Both are older, pineal-gland-linked research peptides that get compared a lot, even though they were studied for different things: DSIP for sleep architecture, Epithalon for telomere biology and pineal function. We published a full comparison this week if you want the mechanism side of it.
| Per-mg range | Vendors indexed | |
|---|---|---|
| DSIP | $2.70–$12.48/mg | 26 |
| Epithalon (10mg vials) | $2.25–$5.40/mg | 23 |
Epithalon's per-mg cost drops further at larger vial sizes and rises at very small ones (1mg vials), which is typical across most peptides, not specific to this pair. See all current prices
Read the comparison: DSIP vs. Epithalon
This week's code
- USA30 at Amino Club: 30% off, expires July 11
DSIP, Epithalon, and the peptides discussed in the PCAC story above are research compounds, not FDA-approved treatments. Nothing here is medical, legal, or regulatory advice. If you're weighing a health decision or want to submit a public comment, that's worth doing with current information straight from the source.